Neoadjuvant Chemo–IO

This discussion will compare strategies for sequencing immunotherapy in gastroesophageal malignancies, examining emerging clinical trial data, biologic rationale, and practical considerations influencing treatment selection. Faculty will address potential impacts on pathologic response, survival outcomes, and toxicity, as well as provide their expert perspectives on integrating immunotherapy across the perioperative continuum of care. This discussion will cover the biologic rationale and emerging clinical trial data supporting early integration of immunotherapy to enhance pathologic response and long-term outcomes. Faculty will address patient selection, safety considerations, and implications for surgical management, guiding learners on how neoadjuvant chemo-IO may reshape treatment paradigms in gastroesophageal cancer.